CHME.US China Medicine Corporation
- Market cap
- USD 1.53M
- P/E
- -
- P/B
- 0.07x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CHME.US undervalued?
Graham numberThe Graham number of China Medicine Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Medicine Corporation fundamental analysis
No fundamental analysis for China Medicine Corporation yet.
China Medicine Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Medicine Corporation
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, a…
Full company profileChina Medicine Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Medicine Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 10.4M | - | 24.0M | 42.1M | 53.6M | 64.8M | - | - |
| Gross Profit | 3.24M | - | 8.97M | 12.4M | 15.6M | 19.0M | - | - |
| Operating Income | 2.42M | -32.5K | 6.18M | 8.41M | 10.9M | 12.3M | -7.48K | -23.0K |
| EBITDA | 2.54M | -32.5K | 6.35M | 9.20M | 11.3M | 13.3M | -7.48K | -23.0K |
| Net Income | 2.94M | -32.5K | 4.79M | 6.88M | 9.13M | 1.72M | -7.48K | -23.0K |
| EPS | 0.39 | 0.00 | 0.63 | 0.50 | 0.60 | 0.11 | 0.00 | 0.00 |
| Balance Sheet | ||||||||
| Total Assets | 3.36M | 2.00K | 14.6M | 32.6M | 44.7M | 66.8M | - | - |
| Total Liabilities | 1.28M | 32.4K | 600K | 863K | 1.08M | 21.3M | - | - |
| Shareholders' Equity | 2.08M | -30.4K | 13.1M | 30.9M | 42.8M | 45.0M | - | - |
| Cash & Short-term Investments | 244K | 2.00K | 371K | 5.77M | 2.79M | 472K | - | - |
| Total Debt | - | 32.4K | - | - | - | 9.51M | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | 2.55M | -32.5K | -2.22M | -2.31M | 4.21M | 17.0M | - | -3.23M |
| Capital Expenditure | 8.72K | 0.00 | 826K | 390K | 2.67M | 3.67M | - | 6.14M |
| Free Cash Flow | 2.54M | -32.5K | -3.04M | -2.70M | 1.54M | 13.3M | - | -9.37M |
| Ratios | ||||||||
| ROE | 141.4% | - | 36.5% | 22.3% | 21.3% | 3.8% | - | - |
| ROA | 87.5% | -1,625.0% | 32.7% | 21.1% | 20.4% | 2.6% | - | - |
| Net Profit Margin | 28.3% | - | 20.0% | 16.3% | 17.0% | 2.7% | - | - |
| Debt to Equity | - | - | - | - | - | 0.21x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Medicine Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2009 | - | - | - |
| 2008 | - | - | - |
| 2007 | - | - | - |
| 2006 | - | - | - |
| 2005 | - | - | - |
| 2004 | USD 2.32M | 0.31 | 79.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns China Medicine Corporation
Ownership data of China Medicine Corporation is not available yet.
China Medicine Corporation company profile
- Company name
- China Medicine Corporation
- Ticker
- CHME.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Pharmaceuticals
- Employees
- 281
- Fiscal year end
- December
- Address
- 2/F, Guangri Tower, Guangzhou, China, 510006
- Phone
- 86 20 8739 1718
- Website
- cmc621.com/cmc/index.php
About China Medicine Corporation
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.
China Medicine Corporation management
3- Mr. Senshan YangChairman, CEO & Chairman of Guangzhou Konzern Medicine Co., Ltd · born 1961
- Mr. Ho Chi FungChief Financial Officer · born 1972
- Ms. Huizhen YuController · born 1980